Marketed by Elanco, it provides modified-live virus (MLV) protection against bovine viral diarrhea (BVD), types 1 and 2, bovine respiratory syncytial virus (BRSV), infectious bovine rhinotracheitis (IBR) and parainfluenza3 (PI3). Each dose also protects against Mannheimia haemolytica and Pasteurella multocida bacteria, and is safe for cattle at all stages of production. 


Respiratory viruses can cause BRD on their own, but they also can compromise the immune system that normally protects cattle against bacteria. This allows bacteria to attack their host and cause severe cases of BRD.


The new product is a combination of two trusted vaccines. Its viral component, Titanium 5, delivers modified-live protection against five important viruses that cause BRD. Its PH-M component provides coverage against two bacteria that are well-known for causing pasteurellosis (part of the BRD complex).


The new vaccine is formulated with a low-reactive, water-soluble adjuvant. The result is a low-volume (2 mL), subcutaneous dose that is consistent with Beef Quality Assurance (BQA) guidelines.


Approved for use in cattle 60 days of age and older, it is backed by noninterference, efficacy and safety research. It is available in convenient 10-dose and 50-dose packages through veterinarians and animal-health distributors. 

—From Elanco news release

PHOTO
Photo courtesy of Elanco.